See how AbbVie Inc. and Broadcom Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
Broadcom Inc. is one of the world’s largest semiconductor companies and has also built a significant presence in infrastructure software. Its chip business is mainly focused on computing and networking, with custom AI accelerators now representing the majority of operations. Broadcom primarily operates as a fabless chip designer, though it retains some in-house manufacturing, including its leading film bulk acoustic resonator filters used in Apple iPhones. On the software side, the company provides virtualization, infrastructure, and security solutions to large enterprises, financial institutions, and government customers. Broadcom has grown through consolidation, combining businesses from legacy Broadcom and Avago Technologies in semiconductors, along with VMware, Brocade, CA Technologies, and Symantec in software.